Patents by Inventor Stefan Klostermann
Stefan Klostermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200216880Abstract: Herein is reported a method for selecting a variant of a parental antibody variable domain encoding nucleic acid, wherein the parental antibody variable domain amino acid sequence encoded by said encoding nucleic acid has at least one developability hot spot, the method comprising the steps of (i) providing a multitude of DNA-containing samples (genomic material of antibody secreting B-cell) each including one or more antibody variable domain encoding nucleic acids; (ii) performing PCR amplification of said antibody variable domain encoding nucleic acids of (i) using consensus sequence-specific primers to obtain amplification products (wherein said consensus sequence-specific primers bind to consensus sequences that are common to a plurality of genes within the genetic loci set, thereby generating a pool of amplification products); (iii) sequencing a plurality of said amplification products obtained in step (ii) in order to determine the relative proportion of each nucleotide at each position in a sequencingType: ApplicationFiled: September 5, 2019Publication date: July 9, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Guy GEORGES, Stefan KLOSTERMANN, Alain TISSOT, Francesca ROS, Alexander BUJOTZEK, Clemens WRZODEK, Frederic SCHULTZ
-
Patent number: 10611840Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: January 24, 2018Date of Patent: April 7, 2020Assignee: Hoffman-La Roche Inc.Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Patent number: 10611841Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: January 24, 2018Date of Patent: April 7, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Publication number: 20200102389Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.Type: ApplicationFiled: May 17, 2019Publication date: April 2, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Jens FISCHER, Meher MAJETY, Stefan DENGL, Georg TIEFENTHALER, Stefan KLOSTERMANN, Claudia KIRSTENPFAD, Esther KOENIGSBERGER, Francesca ROS
-
Publication number: 20200066372Abstract: Herein is reported a method for selecting or deselecting an antibody comprising a) determining for each Asp and Asn residue in an antibody Fv region the conformational flexibility of the C?-atom using a homology model ensemble, b) determining for each Asp and Asn residue in an antibody Fv region the size of the amino acid residue C-terminal to the Asp or Asn residue, and c) selecting an antibody in which the Ca-atom is conformationally inflexible and/or the Asp or Asn has a big C-terminal amino acid residue, or deselecting an antibody in which the C?-atom has a moderate to high conformational flexibility and/or the Asp or Asn has a small C-terminal amino acid residue.Type: ApplicationFiled: August 2, 2019Publication date: February 27, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Hubert KETTENBERGER, Stefan KLOSTERMANN, Florian LIPSMEIER, Apollon PAPADIMITRIOU, Jasmin SYDOW-ANDERSEN
-
Patent number: 10418126Abstract: Herein is reported a method for selecting or deselecting an antibody comprising a) determining for each Asp and Asn residue in an antibody Fv region the conformational flexibility of the C?-atom using a homology model ensemble, b) determining for each Asp and Asn residue in an antibody Fv region the size of the amino acid residue C-terminal to the Asp or Asn residue, and c) selecting an antibody in which the C?-atom is conformationally inflexible and/or the Asp or Asn has a big C-terminal amino acid residue, or deselecting an antibody in which the C?-atom has a moderate to high conformational flexibility and/or the Asp or Asn has a small C-terminal amino acid residue.Type: GrantFiled: March 4, 2016Date of Patent: September 17, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Hubert Kettenberger, Stefan Klostermann, Florian Lipsmeier, Apollon Papadimitriou, Jasmin Sydow-Andersen
-
Publication number: 20190248916Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: December 20, 2018Publication date: August 15, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Joerg Benz, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Lydia Jasmin Hanisch, Alexander Bujotzek, Wei Xu
-
Patent number: 10253104Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3?, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.Type: GrantFiled: August 3, 2015Date of Patent: April 9, 2019Assignee: ENGMAB AGInventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Lydia Jasmin Hanisch, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
-
Publication number: 20180282410Abstract: The present invention generally relates to bispecific antigen binding molecules for activating T cells, more particularly bispecific antigen binding molecules for activating T cells targeting the Robo 4 receptor. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. In addition, the invention also relates to antibodies that specifically bind to Robo 4.Type: ApplicationFiled: September 29, 2016Publication date: October 4, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Oliver AST, Marina BACAC, Sabine BAUER, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Samuel MOSER, Christiane NEUMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMAÑA, Tina WEINZIERL
-
Patent number: 10047162Abstract: Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.Type: GrantFiled: August 21, 2015Date of Patent: August 14, 2018Assignee: HOFFMANN-LA ROCHE INC.Inventors: Hubert Kettenberger, Stefan Klostermann, Ulrich Kohnert, Sebastian Neumann
-
Publication number: 20180222980Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: January 24, 2018Publication date: August 9, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane JAEGER, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
-
Publication number: 20180222981Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: January 24, 2018Publication date: August 9, 2018Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane JAEGER, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
-
Patent number: 9957331Abstract: Herein are reported the cell lines DSM ACC3006, DSM ACC3007, and DSM ACC3008, as well as the antibodies obtained from the cell lines and the use of an antibody obtained from the cell lines in an immunoassay. Also are reported antibodies binding to human or chimpanzee IgG and not binding to canine and marmoset IgG and antibodies specifically binding to an IgG 1 that comprises a kappa light chain constant domain.Type: GrantFiled: October 18, 2010Date of Patent: May 1, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Essig, Stefan Klostermann, Frank Kowalewsky, Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
-
Publication number: 20180100006Abstract: Herein is reported a method for recombinantly producing a polypeptide in a cell comprising the step of cultivating a cell which comprises a nucleic acid encoding the polypeptide, and recovering the polypeptide from the cell or the cultivation medium, wherein each of the amino acid residues of the polypeptide is encoded by at least one codon, whereby the different codons encoding the same amino acid residue are combined in one group and each of the codons in a group is defined by a specific usage frequency within the group, whereby the sum of the specific usage frequencies of all codons in one group is 100%, and wherein the usage frequency of a codon in the polypeptide encoding nucleic acid is about the same as its specific usage frequency within its group.Type: ApplicationFiled: December 6, 2017Publication date: April 12, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Stefan Klostermann, Erhard Kopetzki, Ursula Schwarz
-
Patent number: 9914776Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: August 3, 2015Date of Patent: March 13, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Jaeger, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Publication number: 20170349669Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.Type: ApplicationFiled: May 15, 2017Publication date: December 7, 2017Applicant: Hoffmann-La Roche Inc.Inventors: SABINE IMHOF-JUNG, CHRISTIAN KLEIN, STEFAN KLOSTERMANN, JOERG THOMAS REGULA, WOLFGANG SCHAEFER
-
Publication number: 20170306036Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3epsilon, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), r aspartic acid (D) (numbering according to Kabat). Also the manufacture and use of said antibody.Type: ApplicationFiled: August 3, 2015Publication date: October 26, 2017Applicant: ENGMAB AGInventors: Minh Diem VU, Klaus STREIN, Oliver AST, Marina BACAC, Lydia Jasmin HANISCH, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Samuel MOSER, Ramona MURR, Pablo UMANA, Sabine JUNG-IMHOF, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg REGULA, Wolfgang SCHAEFER
-
Publication number: 20170306044Abstract: Bispecific antibodies against CD3epsilon and ROR1 are useful for use in the treatmentof ovarian cancer.Type: ApplicationFiled: October 8, 2015Publication date: October 26, 2017Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RALF HOSSE, CHRISTIAN KLEIN, EKKEHARD MOESSNER, SAMUEL MOSER, RAMONA MURR, PABLO UMANA, SABINE JUNG-IMHOF, STEFAN kLOSTERMANN, MICHAEL MOLHOJ, JOERG REGULA, WOLFGANG SCHAEFER
-
Publication number: 20170306018Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.Type: ApplicationFiled: October 8, 2015Publication date: October 26, 2017Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RALF HOSSE, CHRISTIAN KLEIN, EKKEHARD MOESSNER, SAMUEL MOSER, RAMONA MURR, PABLO UMANA, SABINE JUNG-IMHOF, STEFAN KLOSTERMANN, MICHAEL MOLHOJ, JOERG REGULA, WOLFGANG SCHAEFER
-
Patent number: 9766251Abstract: Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays.Type: GrantFiled: February 20, 2015Date of Patent: September 19, 2017Assignee: HOFFMANN-LA ROCHE INC.Inventors: Ulrich Essig, Stefan Klostermann, Frank Kowalewsky, Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels